Sunshine Heart to Present at The Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference

 

SYDNEY, AUSTRALIA and EDEN PRAIRIE, MN--(Marketwire - Dec 1, 2011) - Sunshine Heart, Inc. (ASX: SHC), today announced that Jeff Mathiesen, Sunshine Heart's Chief Financial Officer, is scheduled to present at Canaccord Genuity's 6th Annual Cardiovascular, Aesthetics and Metabolic Disorders Conference in San Francisco, CA on Tuesday, December 6th at 9:20AM PST.

A live webcast of the presentation will be available under the Webcast section of the Company's website at www.sunshineheart.com.

About Sunshine Heart®
Sunshine Heart is a global medical device company committed to the commercialization of the C-Pulse Heart Assist System, an implantable, non-blood contacting, heart assist therapy for the treatment of moderate to severe heart failure which can be implanted using a minimally invasive procedure. C-Pulse is designed to relieve the symptoms of heart failure through the use of counter-pulsation technology which enables an increase in cardiac output, an increase in coronary blood flow and a reduction in the heart's pumping load. The Company has completed enrollment of an approved U.S. Food and Drug Administration (FDA) 20 patient feasibility clinical trial with the C-Pulse System. Sunshine Heart is a Delaware-based Corporation headquartered in Minneapolis with a subsidiary presence in Australia. The Company has been listed on the ASX since September 2004. For more information, please visit www.sunshineheart.com.



For further information, please contact:

Jeff Mathiesen
Chief Financial Officer
Sunshine Heart, Inc.
T: 952 345 4200